I added a PPMS trial of Ocrelizumab to the phase 3 list, based on this clinicaltrials.gov listing.
On the one hand, this is GREAT news! Any time a new substance enters phase 3 it’s a major step in the right direction. Just as importantly, it is being tested for PPMS, where the need is greatest.
On the other hand, this drug has a bit of a black cloud over it as there was a treatment-related death in the most recent phase 2 MS trial and it was discontinued as an experimental treatment for RA earlier this year due to side-effect concerns.
It’s never straight forward when it comes to treating this disease, is it?